AstraZeneca Sues Mylan Same Day New Symbicort Patent Is Issued

AstraZeneca PLC filed a lawsuit alleging that generic versions of Symbicort proposed by Viatris Inc.’s Mylan Pharmaceuticals infringe a patent issued for the drug, an inhaler for treating asthma, earlier the same day.

The complaint, filed Tuesday in the U.S. District Court for the Northern District of West Virginia, also names as a co-defendant Kindeva Drug Delivery LP, formerly 3M Drug Delivery Systems, which AstraZeneca says will manufacture Mylan’s copycats.

The patent, which expires in July 2023, relates to a formulation comprising formoterol and budesonide for use in treating respiratory diseases. Symbicort’s active ingredients are budesonide ...